Therapeutic drug monitoring in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab: insights from a prospective real-world study

Scandinavian Journal of Gastroenterology 2026 Open access

Read full text
Authors: Camilla Bergsmark, Vendel A. Kristensen, Maren B. Sjåmo, Marte Lie Høivik, Karoline Anisdahl
DOI: 10.1080/00365521.2026.2645083
Cited by: 1
References: 21

Abstract

BACKGROUND AND AIMS: The efficacy and safety of switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX) have been demonstrated across multiple studies, but data on patients treated with high IV doses remain limited. This study aimed to confirm the safety of switching regardless of IV dosing regimen and examine serum drug concentrations during follow-up. METHODS: This prospective single-centre study included adult patients with inflammatory bowel disease in remission on maintenance IV IFX. Patients receiving IV IFX

Fields of Study & Subjects

Inflammatory Bowel Disease Biosimilars and Bioanalytical Methods Systemic Lupus Erythematosus Research

Publication details

Journal / source
Scandinavian Journal of Gastroenterology
Publisher
Informa UK Limited
Volume
61
Issue
6
Pages
633–643
Publication date
28 March 2026
Language
EN